3rd Edition of
International Ophthalmology Conference
March 10-12, 2025 | Rome, Italy
Nanotechnology in Ophthalmology
Nanotechnology is a new concept that will soon become the pinnacle of science and technology. It penetrates using nanometer-sized molecules and has demonstrated its worth in space, medicine, and other fields of science. Because the eye is a small organ that can be easily accessed due to its exposed location, it is an ideal target for nanotechnology. It appears that the "discovery of nanomedicines has reawakened huge aspirations for ophthalmic pharmacotherapy, in which nanostructured drugs are predicted to pass through the eye's limiting barriers." Safe manufacturing procedures and unforeseen biological repercussions of nanomaterial use remain barriers to nanotechnology adoption. These challenges are not insurmountable, and this developing sector is likely to yield innovative treatments for ocular disorders.
- Nanomedicine
- Nano Pharmaceuticals
- Nanostructured Drugs
John David Bullock
Wright State University, United States
Minckler Don S
UCI Gavin Herbert Eye Institute, United States
Kasra Rezaei
University of Washington, United States
Dhruva Drew Gupta
Harvard Medical School, United States
Nour Abou Shousha
Harvard Medical School, United States
George HH Beiko
McMaster Univeresity, Canada
Mustafa Al Ghazi
University Hospital of Wales, United KingdomSubmit your abstract Today
Title : Optic nerve orthograde axonal transport in abusive head trauma suspects
Minckler Don S, UCI Gavin Herbert Eye Institute, United States
Title : Eyes and guts connection: Microbiomes and their role in ocular health
Edward Charles Kondrot, Healing the Eye Wellness Center, United States
Title : Ultra-Widefield protocol enhances automated classification of diabetic retinopathy severity with OCT angiography
Kasra Rezaei, University of Washington, United States
Title : Why was Leonhard Euler blind?
John David Bullock, Wright State University, United States
Title : Lumevoq gene therapy in leber hereditary optic neuropathy
Magali Taiel, GenSight Biologics, France
Title : Developing resilience-based treatments for glaucoma
Simon John, Columbia University, United States